Published in AIDS Weekly, September 11th, 2006
Results from this 48-week analysis show that patients achieved virologic and immunologic improvements when taking tipranavir oral solution combined with ritonavir (tipranavir/r), as part of combination antiretroviral therapy. This study of tipranavir oral solution is the first to evaluate an antiretroviral drug in highly pre-treated HIV-1 infected pediatric patients.
Tipranavir oral solution is an investigational formulation of Aptivus (tipranavir)....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-09-11)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.